The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G
2007

HIV-1 Vif Dimerization and Its Role in Viral Infectivity

publication Evidence: moderate

Author Information

Author(s): James H. Miller, Vlad Presnyak, Harold C. Smith

Primary Institution: OyaGen, Inc.

Hypothesis

The dimerization domain of HIV-1 Vif is essential for blocking the incorporation of APOBEC3G into viral particles.

Conclusion

Blocking Vif dimerization allows more APOBEC3G to be incorporated into HIV-1 virions, reducing their infectivity.

Supporting Evidence

  • Peptide antagonists of Vif dimerization suppressed HIV-1 infectivity.
  • Blocking Vif dimerization increased the incorporation of hA3G into viral particles.
  • The study confirmed that Vif dimerization is a valid target for therapeutic development.

Takeaway

HIV-1 uses a protein called Vif to stop a defense protein from getting into the virus. If we block Vif, the defense protein can get in and help stop the virus.

Methodology

The study used peptide antagonists to disrupt Vif dimerization and assessed their effects on HIV-1 infectivity in cell cultures.

Limitations

The study primarily used overexpressed hA3G, which may not reflect natural conditions.

Statistical Information

P-Value

p ≤ 0.01

Statistical Significance

p ≤ 0.01

Digital Object Identifier (DOI)

10.1186/1742-4690-4-81

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication